InnoCan Pharma Corporation
INNPF
$0.132
-$0.0031-2.30%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 192.24% | 271.49% | 388.86% | 433.69% | 587.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 192.24% | 271.49% | 388.86% | 433.69% | 587.43% |
| Cost of Revenue | 158.30% | 236.93% | 391.29% | 272.06% | 161.94% |
| Gross Profit | 196.52% | 275.76% | 388.53% | 468.26% | 764.41% |
| SG&A Expenses | 123.05% | 167.99% | 151.27% | 104.25% | 71.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.09% | 153.06% | 136.27% | 97.86% | 65.90% |
| Operating Income | 71.69% | 33.35% | 34.38% | 39.31% | 39.44% |
| Income Before Tax | 107.23% | 25.72% | 8.23% | -3.76% | -39.03% |
| Income Tax Expenses | 134,300.00% | 92,500.00% | 44,700.00% | 21,300.00% | -- |
| Earnings from Continuing Operations | 78.14% | -5.58% | -1.96% | -9.23% | -39.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -295.29% | -483.25% | -12,166.67% | -459.52% | -305.61% |
| Net Income | 48.19% | -37.12% | -18.63% | -24.93% | -60.67% |
| EBIT | 71.69% | 33.35% | 34.38% | 39.31% | 39.44% |
| EBITDA | 72.31% | 33.71% | 34.68% | 39.50% | 39.68% |
| EPS Basic | 51.52% | -29.13% | -11.93% | -21.19% | -57.14% |
| Normalized Basic EPS | 60.00% | -20.73% | -13.76% | -26.09% | -73.33% |
| EPS Diluted | 50.51% | -27.69% | -10.06% | -15.82% | -48.87% |
| Normalized Diluted EPS | 60.00% | -20.73% | -13.76% | -26.09% | -73.33% |
| Average Basic Shares Outstanding | 8.77% | 7.43% | 4.91% | 3.23% | 1.86% |
| Average Diluted Shares Outstanding | 8.77% | 7.43% | 4.91% | 3.23% | 1.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
